Posted on

Kucer's the Use of Antibiotics: Two Volume Set by M. Lindsay Grayson

By M. Lindsay Grayson

Frontmatter -- colour Plates -- Human Immunodeficiency Virus. Discovery and improvement of Atazanavir / Awny Farajallah, R Todd Bunch, Nicholas A Meanwell -- Discovery and improvement of PL-100, a unique HIV-1 Protease Inhibitor / Jinzi J Wu, Joseph Musto -- Darunavir (Prezista, TMC114): From Bench to health facility, bettering cures for HIV-Infected sufferers / Marie-Pierre de B̌thune, Vanitha Sekar, Sabrina Spinosa-Guzman, Marc Vanstockem, Sandra De Meyer, Piet Wigerinck, Eric Lefebvre -- Discovery and improvement of Tipranavir / Karen R Romines -- TMC278 (Rilpivirine): A Next-Generation NNRTI in section III scientific improvement for Treatment-Naive sufferers / Jerome Guillemont, Katia Boven, Herta Crauwels, Marie-Pierre de B̌thune -- Etravirine: From TMC125 to Intelence: A remedy Paradigm Shift for HIV-Infected sufferers / Koen Andries, Ann Debunne, Thomas N Kakuda, Michael Kukla, Ruud Leemans, Johan Vingerhoets, Brian Woodfall, Marie-Pierre de B̌thune -- Discovery and improvement of Tenofovir Disoproxil Fumarate / Erik De Clercq -- Discovery and improvement of Apricitabine / Susan Cox, John Deadman, Justine Southby, Jonathan Coates -- Discovery and improvement of Maraviroc and PF-232798: CCR5 Antagonists for the remedy of HIV-1 an infection / Patrick Dorr, Paul Stupple -- Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the remedy of HIV-1 an infection / Jayaram R Tagat, Julie M Strizki, Lisa M Dunkle -- Discovery and improvement of HIV-1 access Inhibitors that focus on gp120 / John F Kadow, John Bender, Alicia Regueiro-Ren, Yasutsugu Ueda, Tao Wang, Kap-Sun Yeung, Nicholas A Meanwell -- Discovery of MK-0536: a possible Second-Generation HIV-1 Integrase Strand move Inhibitor with a excessive Genetic Barrier to Mutation / Melissa S Egbertson, John S Wai, Mark Cameron, R Scott Hoerrner -- Discovery and improvement of HIV Integrase Inhibitor Raltegravir / Vincenzo Summa, Paola speed -- Elvitegravir: a singular Monoketo Acid HIV-1 Integrase Strand move Inhibitor / Hisashi Shinkai, Masanori Sato, Yuji Matsuzaki -- Hepatitis C Virus. Discovery and improvement of Telaprevir / Anne-Laure Grillot, Luc J Farmer, B Govinda Rao, William P Taylor, Ilan S Weisberg, Ira M Jacobson, Robert B Perni, Ann D Kwong -- Discovery and improvement of BILN 2061 and Follow-Up BI 201335 / Montse Llin̉s-Brunet, Peter W White -- Intervention of Hepatitis C Replication via NS3-4A, the Protease Inhibitor Boceprevir / Srikanth Venkatraman, F George Njoroge -- Discovery and improvement of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227) / Scott D Seiwert, Karl Kossen, Lin Pan, Jyanwei Liu, Brad O Buckman -- Discovery and improvement of the HCV Protease Inhibitor TMC435 / Pierre Raboisson, Gregory Fanning, Herman de Kock, Asa Rosenquist, Rene Verloes, Kenneth Simmen -- Discovery and scientific evaluate of the Nucleoside Analog Balapiravir (R1626) for the therapy of HCV an infection / Klaus Klumpp, David B Smith -- Discovery and improvement of PSI-6130/RG7128 / Phillip A Furman, Michael J Otto, Michael J Sofia -- Discovery of Cyclophilin Inhibitor NIM811 as a unique healing Agent for HCV / Kai Lin -- HCV Viral access Inhibitors / Flossie Wong-Staal, Guohong Liu, Jeffrey McKelvy -- respiration Syncytial Virus Inhibitors. Discovery of the RSV Inhibitor TMC353121 / Jean-Fraṅois Bonfanti, Gabriela Ispas, Frans Van Velsen, Wieslawa Olszewska, Tom Gevers, Dirk Roymans -- Discovery and improvement of Orally lively RSV Fusion Inhibitors / Nicholas A Meanwell, Christopher W Cianci, Mark R Krystal -- Discovery and improvement of RSV604 / Joanna Chapman, Stuart Cockerill -- Influenza, Hepatitis B, and Cytomegalovirus Inhibitors. Discovery and improvement of Influenza Virus Sialidase Inhibitor Relenza / Robin Thomson, Mark von Itzstein -- Discovery and improvement of Entecavir / Richard Wilber, Bruce Kreter, Marc Bifano, Stephanie Danetz, Lois Lehman-McKeeman, Daniel J Tenney, Nicholas Meanwell, Robert Zahler, Helena Brett-Smith -- Benzimidazole Ribonucleosides: Novel Drug applicants for the Prevention and remedy of Cytomegalovirus ailments / Karen ok Biron, Kristjan S Gudmundsson, John C Drach -- Index

Show description

Read or Download Kucer's the Use of Antibiotics: Two Volume Set PDF

Similar nonfiction_5 books

Management: Meeting and Exceeding Customer Expectations, 9th Edition

Administration: assembly AND EXCEEDING consumer expectancies, 9th variation is a finished survey of the foundations and practices of administration as they're being utilized all over the world. The content material and lines are based to augment carrying on with topics which are woven into the chapters' narratives: 1) the unending attempt by means of managers and agencies to fulfill or exceed consumer wishes, and a pair of) the necessity of enterprises and their humans to be guided through potent management.

Additional resources for Kucer's the Use of Antibiotics: Two Volume Set

Sample text

Availability of benzathine penicillin varies in some regions; for instance, in the UK it is not available, whereas in Australia and many countries it is freely available. Procaine and benzathine salts of Pen G are known as ‘‘long-acting’’, ‘‘depot’’, or ‘‘repository’’ forms. m. injection site, producing prolonged 2. ANTIMICROBIAL ACTIVITY 2a. Routine susceptibility Since the introduction of Pen G into clinical use, many organisms which were originally highly susceptible have now developed resistance.

5–2 mg/ml, and for the latter 4–64 mg/ml. , 1993). Klare et al. (1992) considered that the overproduction of PBP5 is not the only intrinsic resistance mechanism for enterococci. These authors found that overproduction of PBP5 occurred in E. faecium strains which were moderately Pen G resistant, but when MICs were 128 mg/ml this was no longer so, and other so far unknown mechanisms were presumably involved. Another mechanism of Pen G resistance in the enterococci is betalactamase production. This was first described by Murray and Mederski-Samoraj (1983) for one strain of E.

1993). , 1993). If the strain of E. faecium is not high-level gentamicin resistant (MIC W250–500 mg/ml), then if the Pen G MIC is lower than 200 mg/ml, Pen G and gentamicin combination is synergistic. , 1993). However, if high-level gentamicin resistance is present, then synergism is not observed (Mederski-Samoraj and Murray, 1983). In vitro experiments have shown that increase in Pen G resistance of E. faecalis with changes in PBPs can be obtained by exposure of the strain to stepwise increasing concentrations of Pen G or, to a lesser extent, by exposure to unchanging concentrations for a prolonged time.

Download PDF sample

Rated 4.26 of 5 – based on 36 votes